Medication adherence among adults prescribed imatinib,dasatinib,or nilotinib for the treatment of chronic myeloid leukemia

Abstract

Background

Oral tyrosine kinase inhibitors are the standard of care for chronic myeloid leukemia. Tyrosine kinase inhibitors are administered in an outpatient setting for an indefinite period which may negatively impact adherence. Non-adherence to tyrosine kinase inhibitors is associated with disease progression.

Objectives

To evaluate the need for adherence-enhancing interventions, this study was designed to determine the proportion of chronic myeloid leukemia patients non-adherent to their tyrosine kinase inhibitor regimen. The secondary objective was to identify the influence of patient characteristics on tyrosine kinase inhibitor adherence.

Methods

Cross-sectional retrospective chart and dispensing record reviews were performed to identify patients receiving a tyrosine kinase inhibitor from 1 June 2010 to 31 January 2012. Adherence was evaluated using the medication possession ratio.

Results

A total of 124 patients were included. Thirty-eight (31%) patients were non-adherent to their tyrosine kinase inhibitor regimen. Patients not receiving concurrent medications were more likely to be non-adherent (odds ratio (OR) 2.33, 95% confidence interval (CI) 1.05–5.13, p = 0.04). The median medication possession ratio was 0.95 (IQR = 0.83–1.07). Median medication possession ratio was lower in patients receiving imatinib compared to dasatinib or nilotinib (0.95 vs. 1.00, p = 0.01) and in those less than 50 years old compared to those greater than 50 years old (0.92 vs. 0.97, p = 0.02).

Conclusions

Optimal tyrosine kinase inhibitor adherence in chronic myeloid leukemia patients poses a significant obstacle in achieving best possible outcomes while reducing healthcare costs. In this study, one in three chronic myeloid leukemia patients treated with a tyrosine kinase inhibitor were non-adherent to their regimen. Those at higher risk of non-adherence were on no concurrent medications, less than 50 years old, and those treated with imatinib. Active intervention to improve tyrosine kinase inhibitor adherence should be developed, implemented, and evaluated to improve patient outcomes at our center.

Keywords

Cancer oncology patient adherence chronic myeloid leukemia oral chemotherapy imatinib dasatinib nilotinib

Get full access to this article

View all access options for this article.

References

Cortes

Silver

Kantarjian

. Holland-Frei cancer medicine, 8th ed. CT: Shelton, 2010.

Van Etten R. Clinical manifestation and diagnosis of 3 chronic myeloid leukemia. In: Larson R (ed.) Uptodate, Waltham, MA: www.uptodate.com (accessed 29 May 2012).

De Almeida

Barbosa Pagnano

Sanches Souza

. Adherence to tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) seems to be related to duration of treatment and type of TKI. Haematologica 2010; 95: 343–343. [In: 15th congress of the European Hematology Association, conference publication].

Druker

Guilhot

O’Brien

. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 23–23.

Marin

Bazeos

Mahon

. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381–2388.

Ganesan

Sagar

Dubashi

. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86: 471–474.

Ibrahim

Eliasson

Apperley

. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733–3736.

Breccia

Efficace

Alimena

. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? Cancer Lett 2011; 300: 115–121.

Johnson

Beaulieu

. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61–69.

10.

Bollu

Guo

. Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs. Blood 2009; 114: abstract 4270–abstract 4270. [In: 51st annual meeting of the American Society of Hematology, conference publication].

11.

Darkow

Henk

Thomas

. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481–496.

12.

Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). December 2005, http://www.netscc.ac.uk/hsdr/files/project/SDO_FR_08-1412-076_V01.pdf (2005, accessed 30 May 2012).

13.

Wei

Rafiyath

Liu

. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010; 3: 47–47.

14.

Noens

Van Lierde

De Bock

. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401–5411.

15.

Marin

. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol 2010; 47: 312–318.

16.

Eliasson

Clifford

Barber

. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011; 35: 626–630.

17.

Peterson

Nau

Cramer

. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3–12.

18.

Vermeire

Hearnshaw

Royen

. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331–342.

19.

Doti

Stemmelin

Shanley

. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood 2007; 110: 4553–4553.

20.

St Charles

Bollu

Hornyak

. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood 2009; 114: 2209–2209.

21.

Cortes

Jones

O’Brien

. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398–404.

22.

Saglio

Kim

Issaragrisil

. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

23.

Haynes

Ackloo

Sahota

. Interventions for enhancing medication adherence. Cochrane Rev 2008; 4: 1–159.